David W Shields1, Sadaf Sohrabi2, Evan O Crane3, Chris Nicholas4, Ashish Mahendra5. 1. Department of Orthopaedic Oncology, Glasgow Royal Infirmary, Castle Street, Glasgow, G4 0ET, UK. Electronic address: dave.shields@nhs.net. 2. Wolfson Medical School, University of Glasgow, University Avenue, Glasgow, G12 8QQ, UK. Electronic address: sadafsohrabisedeh@googlemail.com. 3. Department of Trauma and Orthopaedics, Wishaw General Hospital, 50 Netherton Street, Wishaw, ML2 0DP, UK. Electronic address: evancrane@nhs.net. 4. Department of Radiology, Glasgow Royal Infirmary, Castle Street, Glasgow, G4 0ET, UK. Electronic address: Chris.Nicholas@ggc.scot.nhs.uk. 5. Department of Orthopaedic Oncology, Glasgow Royal Infirmary, Castle Street, Glasgow, G4 0ET, UK. Electronic address: ashish.mahendra@ggc.scot.nhs.uk.
Abstract
BACKGROUND AND PURPOSE: Osteoid osteoma is an infrequent but debilitating benign bone lesion which can be successfully managed by percutaneous radiofrequency ablation (RFA). There are few studies investigating the efficacy and follow-up of this treatment. An arbitrary upper limit of 15 mm has been used to differentiate between osteoid osteoma and osteoblastoma with surgery used for lesions above this limit. We aimed to analyse the cases identified from our prospectively maintained database over a ten year period since adoption of this technique in our unit. The primary objectives were to investigate factors which influenced recurrence and the time period at which patients are at risk of this. BASIC PROCEDURES: Consecutive patients with confirmed osteoid osteoma were included. Patient demographics, complications, and recurrence were recorded and multiple regression analysis was performed to investigate causation. MAIN FINDINGS: Within a minimum follow up of 21 months (mean 72), a recurrence rate of 16.3% was noted, higher than the published literature. Cox regression analysis to predict chance of recurrence revealed a relationship between larger lucent diameter and recurrence (p = 0.049, CI 95%, hazard ratio 1.33). CONCLUSIONS: The traditional cut off between osteoid osteoma and osteoblastoma appears less rigidly defined than previously thought and probably represents a progressive scale with larger lesions responding less well to RFA. This study indicates that each millimetre increase represents a ×1.33 chance of recurrence. Clinicians should counsel patients accordingly with lesions approaching the larger limits of this diagnosis.
BACKGROUND AND PURPOSE:Osteoid osteoma is an infrequent but debilitating benign bone lesion which can be successfully managed by percutaneous radiofrequency ablation (RFA). There are few studies investigating the efficacy and follow-up of this treatment. An arbitrary upper limit of 15 mm has been used to differentiate between osteoid osteoma and osteoblastoma with surgery used for lesions above this limit. We aimed to analyse the cases identified from our prospectively maintained database over a ten year period since adoption of this technique in our unit. The primary objectives were to investigate factors which influenced recurrence and the time period at which patients are at risk of this. BASIC PROCEDURES: Consecutive patients with confirmed osteoid osteoma were included. Patient demographics, complications, and recurrence were recorded and multiple regression analysis was performed to investigate causation. MAIN FINDINGS: Within a minimum follow up of 21 months (mean 72), a recurrence rate of 16.3% was noted, higher than the published literature. Cox regression analysis to predict chance of recurrence revealed a relationship between larger lucent diameter and recurrence (p = 0.049, CI 95%, hazard ratio 1.33). CONCLUSIONS: The traditional cut off between osteoid osteoma and osteoblastoma appears less rigidly defined than previously thought and probably represents a progressive scale with larger lesions responding less well to RFA. This study indicates that each millimetre increase represents a ×1.33 chance of recurrence. Clinicians should counsel patients accordingly with lesions approaching the larger limits of this diagnosis.